End-of-day quote
Taipei Exchange
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
29.35
TWD
|
-2.65%
|
|
-3.29%
|
-1.84%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,524
|
1,481
|
2,085
|
2,326
|
3,889
|
4,109
|
Enterprise Value (EV)
1 |
2,298
|
2,133
|
2,962
|
3,143
|
4,923
|
4,946
|
P/E ratio
|
-6.66
x
|
-4.82
x
|
-8.28
x
|
-6.73
x
|
-11.8
x
|
-10.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
88.4
x
|
88.8
x
|
98.8
x
|
59.8
x
|
164
x
|
159
x
|
EV / Revenue
|
133
x
|
128
x
|
140
x
|
80.8
x
|
208
x
|
191
x
|
EV / EBITDA
|
-11.1
x
|
-9.42
x
|
-18.9
x
|
-15
x
|
-21.1
x
|
-21
x
|
EV / FCF
|
-6.53
x
|
-13.2
x
|
-21.5
x
|
-22.9
x
|
-45.4
x
|
-33
x
|
FCF Yield
|
-15.3%
|
-7.55%
|
-4.65%
|
-4.36%
|
-2.2%
|
-3.03%
|
Price to Book
|
1.02
x
|
1.18
x
|
1.57
x
|
1.74
x
|
3.77
x
|
3.52
x
|
Nbr of stocks (in thousands)
|
80,000
|
80,494
|
100,744
|
116,279
|
116,957
|
137,409
|
Reference price
2 |
19.05
|
18.40
|
20.70
|
20.00
|
33.25
|
29.90
|
Announcement Date
|
3/27/19
|
3/30/20
|
3/26/21
|
3/28/22
|
3/29/23
|
3/13/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
17.23
|
16.68
|
21.11
|
38.9
|
23.65
|
25.85
|
EBITDA
1 |
-207.2
|
-226.4
|
-156.7
|
-209.4
|
-232.8
|
-235.7
|
EBIT
1 |
-231
|
-299.7
|
-240.6
|
-294
|
-318.1
|
-320.5
|
Operating Margin
|
-1,340.1%
|
-1,796.37%
|
-1,139.78%
|
-755.76%
|
-1,345.12%
|
-1,239.87%
|
Earnings before Tax (EBT)
1 |
-224.5
|
-311.4
|
-250.4
|
-301.8
|
-327.9
|
-338
|
Net income
1 |
-222.1
|
-311.4
|
-250.4
|
-301.8
|
-327.9
|
-338
|
Net margin
|
-1,288.59%
|
-1,866.6%
|
-1,186.25%
|
-775.74%
|
-1,386.55%
|
-1,307.64%
|
EPS
2 |
-2.860
|
-3.820
|
-2.500
|
-2.970
|
-2.823
|
-2.810
|
Free Cash Flow
1 |
-351.8
|
-161
|
-137.8
|
-137.2
|
-108.4
|
-150.1
|
FCF margin
|
-2,041.39%
|
-965.16%
|
-652.74%
|
-352.6%
|
-458.21%
|
-580.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/19
|
3/30/20
|
3/26/21
|
3/28/22
|
3/29/23
|
3/13/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
774
|
652
|
876
|
817
|
1,034
|
837
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-3.738
x
|
-2.879
x
|
-5.594
x
|
-3.902
x
|
-4.441
x
|
-3.552
x
|
Free Cash Flow
1 |
-352
|
-161
|
-138
|
-137
|
-108
|
-150
|
ROE (net income / shareholders' equity)
|
-15.6%
|
-20.4%
|
-17.3%
|
-22.6%
|
-27.7%
|
-30.7%
|
ROA (Net income/ Total Assets)
|
-6.07%
|
-7.32%
|
-5.75%
|
-7.04%
|
-7.72%
|
-7.61%
|
Assets
1 |
3,658
|
4,255
|
4,352
|
4,289
|
4,249
|
4,439
|
Book Value Per Share
2 |
18.60
|
15.60
|
13.20
|
11.50
|
8.820
|
8.500
|
Cash Flow per Share
2 |
1.600
|
1.710
|
2.030
|
1.900
|
0.5500
|
0.5700
|
Capex
1 |
204
|
51.3
|
48.2
|
21.3
|
10.7
|
30
|
Capex / Sales
|
1,183.82%
|
307.48%
|
228.18%
|
54.77%
|
45.43%
|
116.2%
|
Announcement Date
|
3/27/19
|
3/30/20
|
3/26/21
|
3/28/22
|
3/29/23
|
3/13/24
|
|
1st Jan change
|
Capi.
|
---|
| -1.84% | 124M | | +6.66% | 72.48B | | +31.10% | 10.32B | | +28.34% | 4.82B | | -20.02% | 4.59B | | +18.94% | 3.72B | | +22.06% | 2.21B | | -36.80% | 1.88B | | -42.53% | 1.8B | | -0.50% | 1.64B |
Specialty & Advanced Pharmaceuticals
|